Why Most Countries Won’t Benefit From Moderna And Pfizer’s Covid-19 Vaccines
That the Moderna and Pfizer Covid-19 vaccines demonstrated efficacy in more than 90 percent of phase 3 trial participants is cause for celebration. Developed at breakneck speed…
